Dual [⁶⁸Ga]DOTATATE and [¹⁸F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score.

ABSTRACT:

Background

Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are heterogeneous in clinical course, biology, and outcomes. The NETPET score predicts survival by scoring uptake on dual [⁶⁸Ga]DOTATATE and [¹⁸F]FDG PET/CT scans. We aimed to validate previous single-centre findings in a multicentre, international study.

Methods

Dual scans were assigned a NETPET score of P1 (DOTATATE positive/FDG negative), P2-4 (DOTATATE positive/FDG positive), or P5 (DOTATATE negative/FDG positive). NETPET score, histological grade, age at diagnosis, and presence/absence of extrahepatic disease were compared to overall survival/time to progression on univariate and multivariate analysis.

Results

319 metastatic/unresectable GEPNEN patients were included. The N

SUBMITTER: Chan DL 

PROVIDER: S-EPMC9938218 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature